Durect News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.08.24	DURECT Corp. Q2 Loss Decreases, Beats Estimates (RTTNews)
27.03.24	DURECT Corp. Q4 Loss decreases, beats estimates (RTTNews)
04.03.24	DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line (RTTNews)
06.02.23	Pre-market Movers: RSLS, KAL, AWIN, AEI, CTLT… (RTTNews)
26.09.22	Innocoll To Make $2 Mln Payment To DURECT On First Commercial Sale Of POSIMIR (RTTNews)
05.07.22	DURECT Appoints Timothy Papp As New CFO (RTTNews)
29.07.21	DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs (PR Newswire)
22.07.21	DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29 (PR Newswire)
14.07.21	DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit (PR Newswire)
23.06.21	DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) (PR Newswire)
09.06.21	DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) (PR Newswire)
03.02.21	SAVA Jumps From $7 To $75 In Just 3 Weeks, DRRX Gets FDA Nod, IMVT Pauses Trials, OCGN Catches Eye (RTTNews)
04.08.20	Pre-market Movers In Healthcare Sector: ATHE, COCP, CHFS, EVFM, DBVT... (RTTNews)
01.07.20	DURECT Begins Patient Recruitment In Phase 2 Study Of DUR-928 In COVID-19 Patients (RTTNews)
17.01.20	FDA Panel Split On DURECT's Drug, Intellipharma Plunges, BNTX To Acquire NTGN (RTTNews)
16.01.20	KALA Strides, NKTR Plunges, RMTI In Deal With Sun Pharma, DRRX Faces FDA Panel (RTTNews)
03.01.20	DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz (RTTNews)
31.12.19	Biotech Stocks Facing FDA Decision In January 2020 (RTTNews)
11.11.19	What Awaits ASMB, DRRX, EIGR At The Liver Meeting? (RTTNews)
23.09.19	What Awaits Durrect In Q4? (RTTNews)
18.07.19	FDA Nod For MRK's Antibiotic; DRRX Awaits Big Day In Dec., Airxpanders Goes Bust (RTTNews)
06.05.19	Have You Marked Your Calendar For DURECT? (RTTNews)
31.07.18	FDA Greelinghts PGNX' Azedra, MYND Delighted, CORV Looks Ahead With Hope (RTTNews)
26.07.18	Biotech Stocks Facing FDA Decision In August (RTTNews)
27.06.18	PTIE Bleeds On FDA Snub, Starpharma Shines, FOLD Unfolds Plans, AKAO Disappoints (RTTNews)
29.05.18	Biotech Stocks Facing FDA Decision In June (RTTNews)
09.05.18	DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine) (PR Newswire)
02.05.18	DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update (PR Newswire)
25.04.18	DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (PR Newswire)
24.04.18	DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call (PR Newswire)
04.04.18	Smart Cannabis Signs Collaboration Deal with Dyna-Gro® to Distribute and Test New Advanced Nutrient Solutions (PR Newswire)
29.03.18	DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis (PR Newswire)
20.03.18	DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER (PR Newswire)
01.03.18	DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs (PR Newswire)
26.02.18	DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) (PR Newswire)
22.02.18	DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call (PR Newswire)
20.02.18	DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) (PR Newswire)
14.02.18	DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics (PR Newswire)
09.01.18	Regpack Introduces Purchase Protection to the Registration Market (PR Newswire)
13.12.17	DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot (PR Newswire)
01.11.17	DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
26.10.17	DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call (PR Newswire)
19.10.17	DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint (PR Newswire)
04.10.17	ECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT Slumps (RTTNews)
02.10.17	DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement (PR Newswire)
20.09.17	DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development (PR Newswire)
09.08.17	TEDxSeattle Announces First Wave of 2017 Speakers (PR Newswire)
08.08.17	DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
08.08.17	ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan (PR Newswire)
07.08.17	Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Durect

Aktien Top/Flop

Meistgelesene Nachrichten